agreement
Forest Laboratories, Inc. and Phenomix Corporation in $340 Million Diabetes Deal
Forest Laboratories and Phenomix Corporation have entered into a definitive collaboration agreement to develop and commercialize dutogliptin (PHX1149) in North America. Dutogliptin is Phenomix’ proprietary orally administered, small molecule dipeptidyl-peptidase-4 (DPP-4) inhibitor currently undergoing Phase 3 clinical development in Type 2 diabetes mellitus.
Terms
——————————-
Codevelopment and Copromotion
Upfront: $75M
Milestones: $340M
Forest will pay Phenomix a royalty on North American [...]
GlaxoSmithKline and AFFiRiS Ink Alzheimer’s Disease Vaccine Deal
GlaxoSmithKline Biologicals and AFFiRiS GmbH announced the execution of a collaboration agreement granting GSK exclusive rights to AFFiRiS’s Alzheimer’s disease vaccine programmes, aimed at treating Alzheimer’s by targeting beta-amyloid.
As part of the agreement, GSK is acquiring exclusive rights to develop and commercialise two Alzheimer’s disease vaccine candidates that are based on AFFiRiS AFFiTOPE technology and [...]
Maxygen and Astellas Ink Deal for Autoimmune Diseases
Maxygen and Astellas announced a global agreement under which Astellas will receive worldwide rights to commercialize MAXY-4 lead candidates for all autoimmune diseases and transplant rejection. MAXY-4 is Maxygen’s preclinical program to create a next-generation CTLA4-Ig protein for rheumatoid arthritis, transplant rejection and other autoimmune indications.
The companies will co-develop MAXY-4 candidates for rheumatoid arthritis and [...]
BMS Picks Up KAI-9803
A little over a month after Daiichi Sankyo (post-merger) ditched their license for KAI-9803, Bristol-Myers Squibb agreed to a partnership agreement with similar terms. Originally, KAI received $20 million upfront from Sankyo, as well as potential milestone payments of up to $300 million for two initial indications and milestone payments on any future delta PKC [...]
Astellas Pharma and CoMentis Sign $760M Alzheimer’s Deal
Astellas Pharma, Inc. and CoMentis, Inc. announced today that the companies have entered into an agreement to develop products from CoMentis’ beta-secretase inhibitor program, including the recently initiated, phase 2, lead candidate compound CTS-21166, an oral beta-secretase inhibitor for the treatment of Alzheimer’s disease. The agreement also includes a research collaboration to develop additional beta-secretase [...]
Recent Comments